HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $5 to $10.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $5 to $10.